BioSkryb Genomics, Inc.

The DNA-informed, single-cell multiomic platform
powering research and therapeutic breakthroughs,
diagnostic innovation, and datasets for AI-driven discovery.

[BioSkryb Genomics, Inc. @bioskryb]

BioSkryb Genomics today announced the execution of an exclusive license to a patent co-owned by Stanford University and the @czbiohub SF covering a method for combined single-cell DNA methylation and genome variation analyses.

https://t.co/AELKkr7fUe

[BioSkryb Genomics, Inc. @bioskryb]

We are thrilled to announce the recipients of our Kick Start Your Research Initiative in Cancer Genomics Grant Program with @UltimaGenomics.

Congratulations to Drs. Pavel Sumazin, Joshua Campbell, and Sarah Mazzilli!

[BioSkryb Genomics, Inc. @bioskryb]

Accelerate Your Oncology Research with New Grant Support!
BioSkryb Genomics and @UltimaGenomics have launched a new Grant Program to help move your cancer genomics research forward.
👇 Learn more and apply before June 20th:
https://t.co/XsZiTpAu4n

[BioSkryb Genomics, Inc. @bioskryb]

The latest issue of The Lab Report, our monthly newsletter, is hitting inboxes later this week. From product announcements to new publications to upcoming events, sign up today to hear the latest from BioSkryb.
https://t.co/a4XlZRI24w

[BioSkryb Genomics, Inc. @bioskryb]

Our single-cell genomics experts are here to supercharge your neuroscience research initiatives by leveraging the power of BioSkryb’s single-cell technologies with ResolveServices℠. Contact ResolveServices to learn more. https://t.co/trGbgrWVn6

[BioSkryb Genomics, Inc. @bioskryb]

We love sharing how our customers have used BioSkryb products and services to enable their research.

Check out our website for more customer testimonials!
https://t.co/SXuGutm1kI

[BioSkryb Genomics, Inc. @bioskryb]

The BaseJumper® Bioinformatics Platform is designed to provide bioinformatics analysis at scale. Learn more: https://t.co/qaHDRhL455

[BioSkryb Genomics, Inc. @bioskryb]

Next month, join Victor Weigman at the @agbt General Meeting February 23-26th on Marco Island, Florida. He will present a poster titled “A high-plexity exome solution tailored for sensitive variant detection in single cells”.

[BioSkryb Genomics, Inc. @bioskryb]

Learn how Chung et al. used cell-type-resolved mosaicism to reveal clonal dynamics of the human forebrain with ResolveOME and other cutting-edge techniques: https://t.co/nqQWthjyTR

[BioSkryb Genomics, Inc. @bioskryb]

Recently we asked our VP of R&D, Jon Zawistowski, PhD to share his thoughts on the future of multiomics. He shared the following opinions:
https://t.co/lWOMucxzic

[BioSkryb Genomics, Inc. @bioskryb]

Our ResolveServices℠ offerings are growing!
ResolveSEQ MRD is an innovative service offering designed to empower further classification and characterization of the measurable residual disease (MRD) cells in hematologic malignancies.
Read more: https://t.co/GfTOgMIFWf

[BioSkryb Genomics, Inc. @bioskryb]

Check out this protocol by Derks et al. describing a step-by-step workflow for genome-wide analysis of somatic variants using primary template-directed amplification (PTA). https://t.co/hFDFI7JX5n

[BioSkryb Genomics, Inc. @bioskryb]

Curious about trends in multiomics?

Read what several experts, including our CSO Charles Gawad, are excited about in the coming year(s).

#genomics #multiomics #singlecell

https://t.co/wm1KtWolqX

[steven hoffman @hoffman_steven]

#PAG32 is coming up and I will be hosting a fun technology showcase featuring @UltimaGenomics @bioskryb and @TwistBioscience across four talks Monday from 4 to 6pm

[BioSkryb Genomics, Inc. @bioskryb]

Today, we are excited to announce the launch of ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of the measurable residual disease (MRD) cells in hematologic malignancies.

Read more:
https://t.co/60MwBt9SSA

[BioSkryb Genomics, Inc. @bioskryb]

The ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit couples BioSkryb’s whole genome amplification chemistry, primary template-directed amplification (PTA), with a whole transcriptome assay.

[BioSkryb Genomics, Inc. @bioskryb]

Our single-cell genomics experts are here to supercharge your research initiatives by leveraging the power of BioSkryb’s single-cell technologies with ResolveServices℠. From single cells to nuclei, genomes to exomes, partner with us to gain valuable single-cell insights.

[BioSkryb Genomics, Inc. @bioskryb]

The ResolveDNA® Whole Genome Single-Cell Core Kit combines the power of primary template-directed amplification (PTA) with library preparation and adapter ligation to provide a convenient, scalable, and streamlined workflow.

[BioSkryb Genomics, Inc. @bioskryb]

Learn how Ganz et al. used ResolveDNA and other cutting edge techniques to contrast somatic mutation patterns in aging human neurons and oligodendrocytes. https://t.co/VKrAuMohv1

[BioSkryb Genomics, Inc. @bioskryb]

View the webinar recording featuring Ruben van Boxtel, Ph.D. to learn how he and his group at the Princess Máxima Center for Pediatric Oncology use single-cell whole genome sequencing to trace the origins of pediatric leukemia.
https://t.co/0OOjLLM9XV